Franklin Street Advisors Inc. NC Makes New $686,000 Investment in DexCom, Inc. $DXCM

Key Points

• Franklin Street Advisors Inc. has made a new investment of approximately $686,000 in DexCom, Inc., acquiring 7,860 shares in the second quarter.
• Institutional and hedge fund ownership of DexCom is at 97.75%, with several firms like Golden State Wealth Management LLC increasing their holdings significantly.
• DexCom's most recent earnings report showed a revenue increase of 15.2% year-over-year, reporting $1.16 billion for the quarter, exceeding estimates.

Franklin Street Advisors Inc. NC bought a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 7,860 shares of the medical device company's stock, valued at approximately $686,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Golden State Wealth Management LLC increased its holdings in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after purchasing an additional 264 shares in the last quarter. Zions Bancorporation National Association UT purchased a new position in shares of DexCom in the 1st quarter worth $27,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom in the 1st quarter worth $37,000. Alpine Bank Wealth Management purchased a new position in shares of DexCom in the 1st quarter worth $40,000. Finally, Private Trust Co. NA boosted its stake in shares of DexCom by 99.4% in the 1st quarter. Private Trust Co. NA now owns 672 shares of the medical device company's stock worth $46,000 after buying an additional 335 shares during the last quarter. Institutional investors own 97.75% of the company's stock.

Insiders Place Their Bets

In other news, Director Kyle Malady sold 667 shares of the business's stock in a transaction dated Friday, September 5th. The stock was sold at an average price of $80.86, for a total value of $53,933.62. Following the transaction, the director directly owned 22,667 shares in the company, valued at $1,832,853.62. The trade was a 2.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president directly owned 94,102 shares in the company, valued at $7,555,449.58. This trade represents a 0.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 6,849 shares of company stock valued at $564,733 over the last three months. Insiders own 0.32% of the company's stock.

DexCom Price Performance

Shares of DexCom stock opened at $67.05 on Friday. The stock's 50-day simple moving average is $76.31 and its 200-day simple moving average is $77.88. DexCom, Inc. has a 52 week low of $57.52 and a 52 week high of $93.25. The company has a market capitalization of $26.29 billion, a price-to-earnings ratio of 46.56, a PEG ratio of 1.39 and a beta of 1.47. The company has a quick ratio of 1.35, a current ratio of 1.52 and a debt-to-equity ratio of 0.48.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its quarterly earnings data on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same period in the previous year, the business earned $0.43 earnings per share. The business's revenue was up 15.2% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. As a group, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on DXCM shares. The Goldman Sachs Group dropped their price target on DexCom from $104.00 to $89.00 and set a "buy" rating on the stock in a research note on Wednesday. Oppenheimer downgraded DexCom from an "outperform" rating to a "market perform" rating in a research note on Monday, September 8th. Piper Sandler raised their price target on DexCom from $90.00 to $100.00 and gave the stock an "overweight" rating in a research note on Thursday, July 31st. Barclays raised their price target on DexCom from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Robert W. Baird lowered their target price on DexCom from $112.00 to $90.00 and set an "outperform" rating on the stock in a research report on Friday, September 26th. Three analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $98.32.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.